Halozyme Therapeutics, Inc.
HALO
$71.48
$0.751.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 205.97% | -180.81% | 6.09% | 39.85% | -13.81% |
| Total Depreciation and Amortization | 26.44% | 30.66% | -0.40% | 0.26% | 0.17% |
| Total Amortization of Deferred Charges | 15.13% | 4.95% | 0.32% | 0.33% | 0.11% |
| Total Other Non-Cash Items | -94.07% | 767.12% | 833.92% | -33.70% | 203.01% |
| Change in Net Operating Assets | -177.84% | 83.82% | 36.67% | -1,331.52% | -70.55% |
| Cash from Operations | -17.78% | 22.64% | 79.11% | -35.35% | -13.59% |
| Capital Expenditure | -162.16% | 52.90% | -93.86% | -64.53% | 68.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.10% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.07% | -107.03% | 136.99% | 196.51% | -375.03% |
| Cash from Investing | 99.61% | -467.93% | 137.78% | 193.77% | -406.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -74.84% | 1,271.13% | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | 87.05% | -8,938.48% | 98.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.67% | 1,169.17% | 92.51% | -8,902.29% | 98.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 161.99% | -179.16% | 412.58% | -289.27% | 257.22% |